A Phase II Double-blind, RandomizEd, Prospective, Placebo Controlled STudy of NanO2TM Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma multiformE: RESTORE
This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy.
NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.
Main Inclusions/Exclusion:
- Histologically confirmed, newly diagnosed primary or secondary glioblastoma
- Planned treatment with 60 Gy of focal radiation administered in 30 fractions, concurrently with temozolomide chemotherapy
- KPS ≥ 70
Contact: Neuro.Research@providence.org